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Abstract
Myelomeningocele and Hydrocephalus in Uganda: The Intersection of Culture,
Supportive Care, and Long-Term Survival. Ernest J Wright III (Sponsored by Dr.
Dennis Spencer). Department of Neurosurgery, Yale School of Medicine, New Haven,
CT.
The treatment of neurosurgical disease in the developing world presents
challenges on numerous levels, not the least of which are the litany of logistical and
infrastructural barriers which stand in the way of delivering care. The scarcity of
neurosurgeons combined with limited mobility in developing countries requires a
reconsideration of approaches to treatment; this is particularly true of
ventriculoperitoneal (VP) shunt insertion for the treatment of hydrocephalus. While VP
shunt implantation is the mainstay of treatment in the United States, it is prone to failure
requiring rapid access to neurosurgical care making shunt dependency a dangerous
proposition in this setting. Endoscopic third ventriculostomy (ETV) offers an alternative
to VP shunt dependency and has been shown to be effective in treating hydrocephalus at
intervals of up to 14 months.
The purpose of this study is to compare the five-year survival for children treated
with endoscopic third ventriculostomy (ETV) to those treated with ventriculoperitoneal
(VP) shunt implantation for myelomeningocele-associated hydrocephalus. Because of the
well known dangers of shunt dependency, it is hypothesized that patients treated with
ETV will have a survival advantage when compared with patients treated with VPS at a
follow-up interval of five years.
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In order to address this hypothesis, a retrospective observational study of children

treated with ETV or VP shunt implantation for myelomeningocele-related hydrocephalus
at the CURE Children’s Hospital of Uganda was carried out, including a control group
consisting of myelomeningocele patients who had not developed hydrocephalus.
Survival status was determined for 128 of 131 study participants (98%). 47/128 (37%)
of patients had expired at five years post-treatment, and 55/128 (42%) patients had expired
at a mean follow-up interval of 84.4 months. Only two cases of death were attributable to
the development of hydrocephalus, none as a result of treatment failure. Kaplan-Meier
survival analysis found no statistically significant relationship between survival and
method of treatment for hydrocephalus (p=0.45), sex of patient (p=0.53), HIV status
(p=0.69), age at repair ( p=0.34), or myelomeningocele level (p=0.12). Survival analysis
performed for districts with community based rehabilitation (CBR) programs and
districts without CBR programs revealed a significant interaction (p=0.001).
The uniformly high mortality across all groups suggests that the chief causes of
long-term mortality are both powerful and independent of hydrocephalus. The only
correlation with survival identified in this study, the presence of a CBR program
providing in-home rehabilitation, fulfills both of these criteria: myelomeningocele patients
require long-term rehabilitation regardless of the development of hydrocephalus and
these programs exert a powerful influence on survival. This substantial difference in longterm survival highlights the fact that children in communities without CBR programs are
not receiving life-saving supportive care, in part due to a lack of parental understanding of
the need for longitudinal care. Established cultural beliefs about myelomeningocele,
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hydrocephalus, and disability in general also hampered efforts to improve survival.
Understanding the practical barriers to the delivery of care in a developing country as well
as the cultural mores through which diseases are understood are critical to effectively
treating disease across cultures and continents.
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Introduction
Mbale, Uganda is a frontier town of sorts: situated five hours from the capital
Kampala, it is the last major stop on the road to the Northwestern border with Sudan
and Kenya. It is an unlikely place to receive neurosurgical care, yet since the year 2000 it
has been home to the CURE Children’s Hospital of Uganda, the sole treatment center
dedicated to pediatric neurosurgery in sub-Saharan Africa. When the Hospital opened, it
brought to the region for the first time the possibility of survival for children born with
hydrocephalus and myelomeningocele, diseases that are most often fatal when untreated.
In two modern neurosurgical operating suites treatment for these diseases is dispensed in
the model of the developed world where children receive an initial surgical procedure at
the hospital and are discharged home with instructions to return to the Hospital for
follow-up care. With such a neurosurgical outpost utilizing proven treatment paradigms,
it is expected that the results should be dramatic: where few children had survived these
diseases in the past, few should be dying of these ailments in the present. The efficacy of
these treatments at intervals beyond 14 months is unknown however, as greater than 70%
of these patients have been lost to follow-up five years after their initial treatment. The
fate of these patients, whether they are surviving or expired, and ultimately whether
treatment has been effective in intervening in the natural course of disease is unknown.
What follows is an attempt to answer this question, but also to better understand how to
adapt a technically complex and technology-dependent field such as neurosurgery to the
setting of a developing country where even the electricity to power the many devices that
modern neurosurgeons depend on cannot be taken for granted.
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Neurosurgery in the Developing World
There are few areas within medicine that have changed as much in the span of a
half-century as neurosurgery. Advancements beginning with the implementation of the
operating microscope in 1957 heralded the age of modern neurosurgery, in which
dauntingly complex pathology is now treated routinely with greater precision, less
morbidity, and lower mortality(1, 2). While the field has made a practice of conscripting
cutting-edge technology to advance the frontiers of neurosurgery, the fact remains that
the overwhelming majority of the six billion citizens of the world have languished with no
neurosurgical care at all. A full 60% of the world’s neurosurgeons administer care to just
14% of the global population; the remaining 40%, 9,686 neurosurgeons, are responsible
for 4.66 billion individuals(3). In addition to inequities in the distribution of neurosurgical
talent, neurosurgically treated illness exerts a disproportionate toll on the citizens of the
developing world. Hydrocephalus, a disease of excess cerebrospinal fluid in the
ventricular system of the brain, has been shown to have a higher prevalence and affect a
larger number of children in East Africa (4). Neural tube defects, debilitating congenital
malformations requiring neurosurgical repair of which the most severe variants are
termed myelomeningocele, are the most frequently encountered congenital malformation
in sub-Saharan Africa(5). Given this disproportionate disease burden and the scarcity of
neurosurgical care, attention must be given to the treatment of neurosurgical diseases in
the third world to ensure that as the frontiers of neurosurgery are advanced in the first
world the remainder of the world’s population is not left behind.
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The necessary solution to this problem lies not in simply exporting first world

treatment paradigms, but in developing treatments tailored to the developing world. The
factors which complicate daily life in developing countries- namely shortcomings of
government, disparities in purchasing power, and a lack of basic infrastructure- also
present unique challenges to the delivery of neurosurgical care. Unstable or inefficient
systems of government prevent the administration of an effective public health apparatus,
disparities in purchasing power place medical devices and pharmaceuticals beyond reach
of the majority of the populace, and a lack of investment in infrastructure presents barriers
to both communication and travel. First world treatment paradigms that take these
things for granted are doomed to fail in this setting. The challenging realities of life in the
developing world necessitate a unique approach to treatment which takes into account
the unique limitations of treating disease in a resource-limited setting.

Hydrocephalus in Uganda
The necessity for a considered approach to neurosurgical disease in the
developing world is illustrated by examining efforts in Uganda to treat hydrocephalus.
Uganda is emblematic of many developing countries in its shortage of trained physicians
rendering specialized care: there are only four neurosurgeons serving its population of
30,000,000 citizens(4, 6). Further exacerbating this scarcity is the fact that most
healthcare providers are located in urban settings while the majority of the populace is
dispersed throughout rural areas: three of the four neurosurgeons are located in the
capital city Kampala while 87% of the population lives outside of urbanized population
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centers(6, 7). For the relatively few Ugandans with access to a neurosurgeon, treatment
remains elusive because of the prohibitive cost of neurosurgical care. The price of the
implantable hardware which comprises the mainstay of treatment for hydrocephalus in
the US is $650, more than one and a half times the gross national income per capita of
$420 and an exorbitant sum for the half of the Ugandan population living on less than a
dollar a day(7, 8). The dearth of neurosurgeons combined with their geographic
sequestration and the lack of affordable treatment options places first world neurosurgical
care outside of the reach of the vast majority of the Ugandan population.
Beyond these myriad challenges endemic to developing countries that stand in the
way of the delivery of medical care, the nature of disease itself can differ when presenting
in the developing world. This point is well illustrated by comparing the causes,
presentation, and sequelae associated with hydrocephalus as it presents in the United
States and Uganda. While hydrocephalus in the United States is most often congenital in
origin(9), hydrocephalus in Uganda is most often secondary to infection(10, 11). In the
United States and most developing nations, hydrocephalus is often detected when a
child’s head circumference departs from normal growth curves during routine health
screening. In Uganda where such screening is rare, hydrocephalus presents at a much
more advanced stage as gross cranial enlargement with overt signs of increased
intracranial pressure such as nausea and vomiting or paralysis of upward gaze(10).
Perhaps most importantly in terms of long-term survival, routine complications that are
considered benign in developed countries can have far more serious consequences in the
setting of a developing country. Hydrocephalus is commonly treated with a
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ventriculoperitoneal shunt (VPS) device that connects the ventricular system of the brain
to the peritoneal cavity, creating a path of egress for excess intraventricular cerebrospinal
fluid. Shunt infection and malfunction are common, manageable complications given
rapid access to neurosurgical care; however in a setting where antibiotics are unavailable
and neurosurgical care a day’s journey or more these complications can be lethal. Given
these fundamental differences in etiology, stage at presentation, and complications, it can
be said that hydrocephalus in the United States and Uganda share a common
pathophysiological basis but little else.
The challenges and barriers to the delivery of healthcare in the developing world
are protean. In Uganda, factors both intrinsic and extrinsic to medicine fashion
hydrocephalus as a distinct pathological entity in a setting of limited resources and
trained personnel. In this setting where simple tasks are complicated and traditionally
manageable complications take on lethal consequences, a departure from conventional
treatment paradigms is required to safely and successfully treat hydrocephalus.

Alternative Approaches to the Treatment of Hydrocephalus
Ventriculoperitoneal shunt insertion is generally held to be the standard of care for
the treatment of hydrocephalus(9). There is no published data on the morbidity and
mortality associated with shunt failure in developing nations. However, the extensive
body of work enumerating the morbidity and mortality associated with shunt dependency
in developed countries suggests that shunts fail at high rates and with regularity
throughout the lifetime of the patient. The most comprehensive trial to date on shunt
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failure found that over half of ventriculoperitoneal shunts fail within two years of
implantation, which is in accord with previously reported failure rates in the literature(1215). Beyond this high initial failure rate, shunt dependency is an ever-present danger as
shunts continue to fail throughout the lifetime of the patient at a rate of 5% per annum(16).
While shunt infection and failure are manageable complications given appropriate
antibiotics and rapid access to neurosurgical care, in a setting where neurosurgeons and
antibiotics are scarce shunt dependency is presumably a dangerous proposition.
Endoscopic third ventriculostomy (ETV) offers an alternative to shunt
implantation and shunt dependency for the treatment of hydrocephalus by creating an
alternative communication between the ventricular system and the subarachnoid space
through fenestration of the floor of the third ventricle. Third ventriculostomy has been
employed since the dawn of modern neurosurgery for the treatment of hydrocephalus: the
first third ventriculostomy was performed by Dandy in 1922 with the first endoscopic
procedure by urologist Walter Mixter in 1923 for which he provided successful treatment
of non-communicating hydrocephalus in a nine-month old child(17). In the ensuing
decades, ETV was performed under stereotactic or ultrasound guidance with varying
degrees of success. The development of silicone and improvements in valve design in the
latter half of the 1950’s led to ETV being superseded by VP shunt implantation for the
treatment of hydrocephalus. In recent years however, advances in neuroendoscopy have
led to a resurgence of interest in ETV.
ETV represents an attractive alternative to VP shunting for the treatment of
hydrocephalus in the developing world. Avoiding implantation of shunt hardware has
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multiple benefits: not only does this obviate the per-procedure cost of a medical implant,
but the risk of infection is reduced substantially because no foreign bodies are introduced
into the patient. Most importantly, an alternative to shunt implantation allows one to
circumvent the dangers of shunt dependency and malfunction that have been well
documented in the United States and throughout much of the developed world.
Through a series of studies performed at the CURE Children’s Hospital of
Uganda (CCHU), Warf et al have sought to define a role for ETV in the treatment of
hydrocephalus in the developing world(8, 10, 18, 19). In a prospective study involving 229
patients with hydrocephalus treated by ETV, Warf et al examined the interaction
between efficacy of ETV and several categorical variables including age at treatment,
cause of hydrocephalus (infectious vs. non-infectious), and patency of the cerebral
aqueduct(10). The overall success rate of 59% obscures the fact that the success of ETV
varied widely between age groups and hydrocephalus of differing etiology. ETV was
highly effective in patients greater than one year of age, with success rates of 81% in cases
of non-postinfectious hydrocephalus (NPIHC) and 90% in postinfectious hydrocephalus
(PIHC). In patients less than a year of age ETV was markedly less effective: 59% of
patients with PIHC and just 40% of patients with NPIHC were successfully treated
with ETV. However, in patients less than one year of age those with an obstructed
cerebral aqueduct (as assessed by fourth ventricular size on ultrasound) were well suited
to treatment by ETV with a success rate of 70%. Based on these findings, Warf contends
that ETV can be considered for primary treatment of hydrocephalus patients older than
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one year of age irrespective of etiology and in patients younger than one year of age with
PIHC and a closed aqueduct.
In a subsequent prospective study involving 550 patients, Warf sought to
characterize the potential benefits of combining choroid plexus cauterization (CPC) with
ETV for the treatment of hydrocephalus(18). While there was no demonstrated benefit in
patients operated on at one year of age or greater, patients less than one year of age
received a significant benefit from the addition of CPC with 66% of patients being
effectively treated in comparison to 47% for ETV alone. Notably, the follow-up intervals
for the two groups differed significantly with a mean follow-up of 9 months for the
ETV/CPC group and 19.2 months for the ETV group, leaving open to question the
possibility that late failure in the ETV/CPC group may have diminished the claimed
benefit of the combined procedure. The benefits of combining ETV with CPC are even
more dramatic in several subgroups: the success rate in NPIHC increased from 38% to
70% with the addition of CPC, and from 35% to 76% in cases of myelomeningoceleassociated hydrocephalus.
Given the promising results of the combined ETV/CPC procedure in the
treatment of myelomeningocele-associated hydrocephalus, Warf et al undertook a
subsequent prospective study involving 115 patients with myelomeningocele-associated
hydrocephalus treated with ETV/CPC to establish the efficacy of the combined
procedure at intervals of one year or greater(19). It was found that ETV/CPC was
effective in 76% of patients at mean follow-up of 19 months. Further, when ETV failure
occurred the failure presented before 10 months in all patients, and before 6 months
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almost 90% of patients. These results suggest that ETV/CPC is an effective treatment for
myelomeningocele-associated hydrocephalus and that treatment failure occurs relatively
early in the post-operative course, averting the lifelong surveillance required with shunt
dependency.
While these studies provide an evidentiary basis for the idea that ETV and
combined ETV/CPC in particular offer a genuine alternative to shunt implantation for
the treatment of hydrocephalus, the all-important question remains whether ETV/CPC
offers an actual survival benefit in comparison to VP shunt implantation for the treatment
of hydrocephalus. This is the question that this study seeks to address.

Statement of Purpose: Specific Hypothesis and Aims
The purpose of this study is to determine the five-year survival for children treated with
ETV or VP shunt implantation for myelomeningocele-associated hydrocephalus between
2000 and 2005 at the CURE Children’s Hospital of Uganda.

Specifically, I hypothesize that either ETV or the combined ETV/CPC procedure is
associated with a lower mortality rate than VP shunt implantation for the treatment of
myelomeningocele-associated hydrocephalus in Southeastern Uganda at a follow-up
interval of five years.

Additional aims of this study include elucidating the long-term outcome for children with
myelomeningocele and hydrocephalus in East Africa, which is heretofore unknown.

	
  

	
  

14	
  

Methods
Study Site
In order to address this hypothesis, the author undertook a retrospective
observational study of children treated with ETV, ETV/CPC, or VPS implantation for
hydrocephalus at the CURE Children’s Hospital of Uganda (CCHU).
CCHU located in Mbale, Uganda is sub-Saharan Africa’s only dedicated
pediatric neurosurgical hospital with one attending neurosurgeon performing over 1,000
procedures per year. CCHU represents an ideal site for this study by virtue of its location
and existing population of hydrocephalus patients treated with ETV and VPS since the
year 2000.
After receiving approval from the institutional review boards of CCHU and
Children’s Hospital Boston, the author relocated to Mbale for patient selection and data
collection under the guidance of Dr. Benjamin Warf and Dr. Dennis Spencer.
Patient Selection
All patients who present to CCHU are entered into a database containing
identifying information, demographic data, diagnosis, and a record of all surgical
procedures and follow-up visits. A list of prospective participants in this study was
generated by searching this database for myelomeningocele patients presenting between
the year 2000 and the end of 2004, yielding a follow-up interval of five years or greater.
Because of the difficulty involved in tracking patients living at distances of more than one
days travel from CCHU, this list was restricted to patients residing in the sixteen
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districts of southeastern Uganda. This list was further restricted to patients who had
survived longer than one month after surgery to eliminate early deaths due to surgical
complications, patients who had a minimum of six months of follow-up to eliminate those
who failed to return for any follow-up appointments, and patients who presented before
six months of age to eliminate cases of delayed myelomeningocele closure.
Experimental design
From these criteria participants in the study were identified and divided into three
groups: two treatment groups and one control group. Participants were segregated by
treatment method into an ETV group including patients who received either an ETV or
combined ETV/CPC, and a VP shunt group. The control group consisted of
myelomeningocele patients who had not required any treatment for hydrocephalus.
The mode of primary treatment was chosen as a function of date at presentation:
patients presenting for the treatment of hydrocephalus between 2000 and October 2001
were treated with VPS, between October 2001 and February 2003 ETV, and from
February 2003 onwards the combined ETV/CPC procedure. Patients who failed
endoscopic treatment were treated with VP shunt implantation.
Outcome measures and patient tracking
The outcomes for this study are survival status and the development of
hydrocephalus. A patient was considered alive if he/she had been seen at the most recent
annual follow-up visit or at greater than five years of age. The survival status of patients
who had missed their last follow-up visit was unknown. Efforts were made to locate these
patients by conducting home visits in the patient’s villages. When families were located,
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the survival of the patient was ascertained and the family was encouraged to return to the
hospital for follow-up care if the patient was alive. Patients who could not be found
despite these exhaustive efforts were considered definitively lost to follow-up and labeled
as such.
A patient was deemed expired if expiration was noted in their medical record or if
the patient’s parents had indicated that the patient had expired at a home visit. In cases
where patients had expired, efforts were made to determine the date of death and
circumstances surrounding the death through an extensive questionnaire (Fig 1) with the
ultimate goal of distinguishing deaths due to hydrocephalus from those of other causes.

Figure 1: Cause of Death Questionnaire featuring open-ended questions and checklist of
symptoms to elicit circumstances surrounding a patient’s death
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Determination of hydrocephalus
Those patients noted to have developed hydrocephalus in their hospital charts
and those who died with a constellation of symptoms indicative of increased intracranial
pressure (nausea and vomiting, headache, progressive lethargy) were considered to have
developed hydrocephalus. Patients up to date with follow up appointments but without
signs or symptoms associated with hydrocephalus were considered not to have developed
hydrocephalus. Patients who were initially lost to follow-up but found alive without
receiving any subsequent neurosurgical treatment after myelomeningocele closure were
considered not treated for hydrocephalus, as were patients who expired without evidence
of increased intracranial pressure and patients definitively lost to follow-up.
Analysis/statistical methods
Kaplan-Meier survival curves were constructed to estimate population survival
from this sample. The log-rank test was used to assess the interaction between survival
and categorical variables including method of treatment, myelomeningocele lesion level,
development of hydrocephalus, gender, and HIV status. The univariate Cox proportional
hazards model was used to examine the effect of age at closure on survival. These analyses
were performed by Dr. Abhaya Kulkarni.

Results
Study Population and Follow-Up Status
Between the year 2000 and 2005, 224 patients had a myelomeningocele closed at
CCHU. 140 patients met the inclusion criteria for this study. 41 patients were known to
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have expired per hospital records; nine because of death attributed to peri-operative
mortality and resultantly were excluded from this analysis of long-term survival (Table
1)(19). 23 patients were seen in clinic at a follow-up interval of greater than five years and
considered surviving for the purposes of this study. Survival status was not known for 76
patients. 71 patients were visited in their home villages. Survival status was determined via
telephone for two patients because of relocation to a district outside of the southeastern
Uganda. Three patients were ultimately lost to follow-up despite all efforts, with survival
status unknown.
Cause of Death

Number of Patients (n=9)

Aspiration

2

Meningitis

2

Ventriculitis

1

Cardiac Arrest (unknown etiology)

1

Anesthesia Complication

1

Suffocation in Bed

1

Unidentified Illness

1

Table 1: Patient mortality during the perioperative period (within one month of surgery).
There were no known failures of treatment for hydrocephalus leading to death in the
perioperative period.
Survival Analyses
F0r the 131 patients included in the analysis, survival status was ascertained for 128
(98%) patients. At five years post-treatment, 81/128 patients were surviving and 47/128
expired, yielding five-year survival and mortality rates of 63% and 37% respectively. At the
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time of data collection, 73/128 (56%) patients were alive at a mean follow-up interval of
84.4 months and 55/128 (42%) patients were found to have expired (Figure 2).

Figure 2: Kaplan-Meier survival curve for all study participants. The initial 12-24 months
following treatment represents the greatest threat to survival, although mortality
continues steadily throughout the time period measured in this study with 37% of study
participants expired at five years after treatment.
Of the 55 patients who expired, a cause of death was ascertained through medical
records or by inference based on the symptoms described in the Cause of Death
Questionnaire for 35 patients (64% of the instances of death). The causes of death are
described in Table 2. Notably, only two cases of death occurred with symptoms
suggestive of increased intracranial pressure consistent with the development of
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hydrocephalus. These two patients had not been treated for hydrocephalus; as such,
neither can be considered treatment failures.
Cause of Death

Number of Patients (n=55)

Unknown

20

Malaria

11

Unspecified febrile illness

5

Anemia, Malnutrition, Dehydration

4

Gastroenteritis

3

New onset hydrocephalus

2

Parental neglect

2

Pneumonia

2

Measles

1

Pyelonephritis

1

Encephalitis

1

Ventriculitis (post-ETV)

1

Severe burns

1

Chiari

1

Table 2: Causes of death in expired study participants, with only two cases of death
attributable to hydrocephalus. Notably, these two patients did not receive treatment for
hydrocephalus and as such cannot be considered failures of treatment.
Survival analysis found no statistically significant relationship between survival
and method of treatment for hydrocephalus (p=0.45, Figure 3a), sex of patient (p=0.53),
HIV status (p=0.69), or age at repair (range 1-126 days of age, mean 20.6 days, median 8
days, p=0.34). The interaction between anatomical myelomeningocele level and survival
approached but failed to achieve statistical significance (p=0.12, Figure 3b).
	
  

	
  

Figure 3a: Kaplan-Meier survival curves for treatment groups and the control group

Figure 3b: Kaplan-Meier survival curves for lumbar/sacral and thoracic/thoracolumbar
myelomeningocele lesions.
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Survival rates varied widely by district, with no discernable geographic trend to explain
the variation in mortality (Figure 4). Because a number of districts contributed very few
patients to this study, with four districts contributing less than five patients (Table 4),
survival analysis by individual district was not attempted. However, survival analysis was
performed for districts with community based rehabilitation (CBR) programs (five
districts, n=48 patients) and districts without CBR programs (11 districts, n=83
patients). This revealed the only statistically significant interaction in this study, between
the presence of a CBR program and five year survival, with a p value of 0.001 (Figure 5).

Figure 4: Mortality rates by district. There is no readily discernable geographic trend
which explains the widely varying mortality rates across districts.
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District

Total Number of
Patients

Number
Surviving (%)

Number
Expired (%)

Bugiri

3

1 (33%)

2 (66%)

Busia

5

3 (60%)

2 (40%)

Iganga

9

5 (56%)

4 (44%)

Jinja

9

4 (44%)

5 (56%)

Kampala

6

5 (83%)

1 (17%)

Kamuli

7

6 (86%)

1 (14%)

Kapchorwa

4

1 (25%)

3 (75%)

Katakwi

2

0 (0%)

2 (100%)

Kumi

14

10 (71%)

4 (29%)

Mayuge

7

4 (57%)

3 (43%)

Mbale

23

7 (30%)

16 (70%)

Mukono

2

0 (0%)

2 (100%)

Pallisa

8

7 (88%)

1 (12%)

Sironko

9

4 (44%)

5 (56%)

Soroti

7

4 (57%)

3 (43%)

Tororo

16

12 (75%)

4 (25%)

Table 4: Patient number, mortality, and survival by individual district. Mortality (and
conversely survival) varied widely across districts. However, the variation in the number
of patients contributed by individual districts prohibited survival analysis by individual
district.
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Figure 5: Kaplan-Meier survival curves for districts with and without community based
rehabilitation (CBR) programs. Note the dramatic divergence between survival curves
and the substantially lower mortality in districts with CBR programs.
Development of hydrocephalus
Of the 131 patients in the study, 67 (51%) had received treatment for hydrocephalus
at the time of data collection. 64 (49%) had not required treatment at the time of data
collection. Of those requiring treatment for hydrocephalus, 39 patients were primarily
treated with endoscopy and 28 primarily treated with shunt implantation. ETV was
successful in 9/17 (53%) patients, and combined ETV/CPC was successful in 17/22 (77%)
patients. 13 patients failed endoscopic treatment and had ventriculoperitoneal shunts
implanted. For the 13 patients who failed endoscopic treatment, all failures occurred
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within nine months and 12/13 (92%) occurred within six months of initial endoscopic
treatment.
Discussion
Little is known about the fate of patients with myelomeningocele in sub-Saharan
Africa. Of the handful of studies reported in the literature, most are descriptive
epidemiological studies(20, 21) and the few studies which attempt to describe the course
of myelomeningocele suffer from a very small sample size or limited follow-up(22-24). The
study reported here involving over 100 patients followed for a minimum of five years with
less than 5% of the study population lost to follow-up is the first to offer insight into the
challenges and consequences of myelomeningocele in sub-Saharan Africa over the long
term.
Determinants of Long-Term Survival
The primary objective of this study is to investigate whether the theorized benefits
of ETV and the avoidance of shunt dependency translate into an actual long-term survival
benefit for patients with myelomeningocele-related hydrocephalus living in a developing
country. Of the 131 patients who met the inclusion criteria for this study, survival status
was ascertained and verified for 128 patients (98%) at a mean follow-up interval of 84.4
months, yielding a robust data set. Based on this data, Kaplan-Meier survival analysis
revealed no interaction between treatment modality and survival at five years posttreatment (p=0.45, Fig 3a). Of interest is the finding that there is no difference in survival
between the treatment groups and the control group, which required no treatment for
hydrocephalus, suggesting that the factors influencing long-term survival may be
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altogether independent of the development or treatment of hydrocephalus. This idea is
supported by the results of attempts to elucidate a cause of death for expired patients:
hydrocephalus was implicated in only 4/55 (7%) of deaths (Fig 2). The fact that there was
no correlation identified between survival and a host of categorical variables (sex, HIV
status, age at repair, anatomical myelomeningocele level) suggests that the chief
determinants of long-term survival may be powerful enough to obviate the more subtle
influence of these categorical variables on survival.
The idea that there are powerful yet unidentified determinants of long-term
survival in this population is lent credence by the exceedingly high mortality rate for the
participants in this study, which stands at 36% at five years of age. This is significantly
higher than 20-25% mortality reported in earlier studies of myelomeningocele in subSaharan Africa; this difference is likely attributable to the shorter follow-up intervals of
these earlier studies(23). By comparison, the most recent UNICEF figures available for
Uganda place the under-5 mortality rate at 18%, making mortality among the participants
of this study double that of the general population. With these figures in mind,
elucidating the primary determinants of mortality is of great importance in prolonging
survival for this population of patients.
Insight into one of the primary determinants of long-term survival can be found
through examining an unexpected finding of this study: the large variability in mortality
across districts. Despite the uniformly high mortality among all study participants,
mortality rates for individual districts ranged from 12-100%. Although this can in part be
attributed to the fact that some districts contributed very small numbers of patients and
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are thus susceptible to errors of random sampling, mortality rates among the three
districts contributing the most patients varied considerably from 25 to 70% suggesting a
genuine and substantial variation in mortality rates across districts.
A closer examination of the three districts contributing the largest number of
patients to the study (Mbale, Tororo, and Kumi) reveals a potential explanation for this
disparity (Fig 4). These three contiguous districts are in close geographical proximity and
as such share many demographic characteristics. Despite this fact, they have dramatically
different mortality rates: 25% in Tororo, 29% in Kumi, and 70% in Mbale. These results
are particularly surprising given that Mbale district, where the CURE Children’s
Hospital of Uganda is located, has one of the highest mortality rates among the districts
included in the study. An extensive search for potential explanatory factors revealed a key
dissimilarity between the two districts with dramatically lower mortality rates and Mbale
district: the existence of a community based rehabilitation (CBR) program that offers inhome support and training to parents of children with myelomeningocele. Survival
analysis of the interaction between the presence of a CBR program and five year survival
revealed a dramatic survival advantage in districts with CBR, as is reflected in the
Kalpan-Meier survival curve (Fig 5).
The Importance of Accessible Long-Term Care
The importance of long-term supportive care for myelomeningocele patients is
well established, with a “life-long commitment by patient, family, and treating medical
personnel” required for long-term survival(25). This is certainly no less true in Uganda,
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although the provision of such comprehensive, longitudinal care is far more difficult given
the lack of a public health infrastructure and the limitations of resources.
Studies in the United States and Europe have demonstrated that long-term
mortality in Myelomeningocele is attributable to secondary effects of disease, most
commonly renal failure as a consequence of urinary incontinence(26, 27). In
acknowledgement of this fact, CCHU has programs in place to provide the materials and
instruction to treat urine and bowel incontinence free of charge. However these programs
are poorly utilized as reflected in the minority of patients returning for follow-up care: of
the 96 patients still alive at the time of the study, 73 (74%) had not returned for follow-up
at CCHU. With critical, life-saving follow-up care being offered free of charge, why were
the majority of patients languishing without such care in their home villages?
The importance of culture and communication in good outcomes
Understanding the reasons for the poor utilization of follow-up care is crucial to
prolonging survival in this group of children. Part of the answer to this quandary is
logistical: travel in Uganda is both difficult and costly, making periodic returns to the
hospital impractical for many. However, conversations with the caregivers of these
patients in their home villages proved to be particularly illuminating in providing insight
into the reasons behind the lack of utilization of follow-up care. This author found that
most parents simply did not understand the need to return for follow-up care. This in turn
stemmed from a general lack of understanding of their child’s disease, treatment, or
prognosis. The majority of parents had no knowledge of the long-term sequelae of
myelomeningocele or of the perils that ensue when these sequelae are left untreated.
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Consequently, many caregivers saw no need to invest the time and money to return to the
hospital. Furthermore, many were misinformed about their child’s prognosis: a number of
parents expressed anger that their child was unable to walk, not having been told that the
myelomeningocele would render their child irreversibly paralyzed and instead believing
that the paralysis was a result of a medical error. This did untold damage to the trust
between caregivers and doctors. While some parents held the expectation that their child
would walk, others believed that an early death was an unavoidable consequence of
disease and consequently abandoned the children with the logic that any resources
invested in the child would be wasted. In a culture where great meaning is ascribed to
names, the names chosen for these children reflect the hopelessness of these parents: Atoh
meaning this child will die, Onono meaning waste of time, or Ajok meaning why has god
cursed me. Clearly, failures in communication led to a lack of understanding and
misplaced expectations which hampered efforts to provide essential longitudinal care,
thereby making a substantial contribution to long-term mortality.
These findings underscore the fact that the education and participation of
caregivers in patient care plans are anything but a peripheral concern, particularly in a
resource-limited setting such as this. While there is a tendency in situations of scarcity to
streamline care by distilling treatment down to its most essential elements in the name of
saving more lives, it would be unwise to do so at the expense of long-term survival.
Ensuring that caregivers have a vested commitment to the treatment plan is an essential
element of treatment, as essential as the initial surgical procedure or longitudinal followup care, all of which are necessary for long-term survival.
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With all this in mind, the role and the need for community-based rehabilitation is

ever more clearly defined. Community-based rehabilitation programs address both of the
barriers to the utilization of long-term supportive care identified here. First, they are
based in the patient’s home communities obviating the need for travel. Second, their
constant presence in the community makes them an ideal vehicle for educating caregivers,
with the ultimate goal being to make these caregivers vested participants in their child’s
plan of care. The efficacy of such a model of delivering longitudinal care is demonstrated
by the clear and dramatic impact on long-term survival revealed in this study. Collectively,
these findings establish the importance and efficacy of community based rehabilitation
programs as well as parental understanding and participation in ensuring the long-term
survival of children living with myelomeningocele and hydrocephalus in Uganda.
A Shift in Focus and New Initiatives at CCHU
The findings of this study have catalyzed a shift in focus and changes in
operational procedure at CCHU. The Hospital celebrated its ten-year anniversary
recently, and while the first ten years of operation were characterized by an effort to
perform a greater number of procedures each successive year, the findings of this study
have shifted attention to ensuring long-term survival after surgery.
Several new initiatives at CCHU aim to improve long-term survival in
myelomeningocele patients. To address the lack of understanding among parents about
their child’s disease and the need for long-term care, the author developed a brief
illustrated lecture that is presented to parents of children admitted to the hospital for
myelomeningocele closure with time following for discussion and questions. In addition
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to explaining the basic pathophysiology of myelomeningocele, the lecture emphasizes the
importance of repositioning children to avoid pressure sores, the necessity of follow-up to
achieve social urine and bowel continence, and the fact that children with
myelomeningocele are capable of growing up to become contributing members of their
communities.
With the help of illustrator Bryan Hong (Yale Medical School, Class of 2010), this
author created a children’s book entitled “Everyone is Different” (Appendix A). This
book, which is being reproduced in Uganda and is given to every child admitted for
myelomeningocele closure at CCHU, covers the same topics as the parent lecture
although from the perspective of a young child living in Uganda coping with the
challenges of paraplegia and urinary incontinence. It is our hope that these resources will
impress upon children, their caregivers, and their communities that these patients with
myelomeningocele are worthwhile individuals capable of contributing to society and
deserving of the care and resources to ensure their survival.
As a direct result of the findings reported here, CCHU has begun funding and
expanding community-based rehabilitation programs throughout southeastern Uganda
in the hopes of replicating the survival benefit identified in this study in communities with
community-based rehabilitation programs. In addition, the Hospital has devoted one
social worker full time to the task of tracking patients who have missed follow-up
appointments to ensure that patients do not fall out of contact with the hospital staff.
Enrollment of myelomeningocele patients for a subsequent follow-up study has already
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begun at CCHU, with data collection to begin in five years in order to assess the impact
of these initiatives on long-term survival.

Conclusions: Practical Barriers to Neurosurgical Care in the Developing
World
The finding that five-year mortality is similar between patients treated with ETV
and VP shunt implantation fails to support the hypothesized survival benefit for
hydrocephalic children in a developing country treated with ETV. However, it would be
premature to conclude from this finding alone that there is no actual survival advantage to
treatment with ETV in this setting. Taken collectively, the findings from this study
demonstrate that long-term rehabilitative care is a far more powerful determinant of
mortality than how hydrocephalus is treated or even whether a patient develops
hydrocephalus at all. It is entirely possible that there exists a difference in long-term
survival between patients treated with ETV and shunt implantation, but that this
difference was obscured by the powerful effect of long-term rehabilitative care.
While this study focuses attention on long-term rehabilitative care as the critical
determinant of long-term survival in this population, on a broader level it illustrates the
profound difficulties of treating neurosurgical disease in a developing country. In
Uganda, hydrocephalus is a unique pathophysiological entity accompanied by barriers to
treatment which are inconceivable to citizens of developed nations. Understanding these
barriers, and the resilient beliefs upon which these barriers are constructed, is critical to
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formulating successful approaches to the treatment of disease. This study demonstrates
that ignoring these beliefs and barriers comes at the cost of patients’ lives.
While it is important to acknowledge and understand the profound differences
between the developed and developing world, we should not forget the commonalities
which transcend cultures and continents. The importance of patient education and
participation in treatment plans as an essential component in producing positive
outcomes has been demonstrated time and again in the developed world. This is no
different in the case of Uganda, and it is perhaps even more important in a setting in
which we seek to deliver care across linguistic and cultural barriers. For all of the many
differences between Uganda and the United States, one should not forget that some
aspects of delivering effective medical care are universal.
The delivery of neurosurgical care to the residents of the developing world is an
imperative which cannot be ignored. Adapting a technically complex and technologically
dependent field to a developing country is fraught with difficulties, however one must not
forget the many practical barriers beyond the operating room which may stand in the way
of providing effective treatment. While cultural beliefs and practical barriers to treatment
may be considered outside of the purview of neurosurgery in the developed world, these
issues must be taken into account if the field of neurosurgery is to provide effective cures
in the developing world. Indeed, it is these practical issues of culture and communication
which must be considered if we are to ensure that as we advance neurosurgical care in
developed nations, that we do not leave the rest of the world behind.
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